{"id":4215,"date":"2026-11-10T09:00:00","date_gmt":"2026-11-10T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4215"},"modified":"2026-11-11T20:45:26","modified_gmt":"2026-11-12T00:45:26","slug":"three-lupus-nephritis-patients-show-early-bcma-car-t-responses","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4215","title":{"rendered":"Three Lupus Nephritis Patients Show Early BCMA CAR T Responses"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"768\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_IASO_Bio_Lupus_Nephritis_Therapeutic_Indications-768x768.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4235\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_IASO_Bio_Lupus_Nephritis_Therapeutic_Indications-768x768.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_IASO_Bio_Lupus_Nephritis_Therapeutic_Indications-300x300.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_IASO_Bio_Lupus_Nephritis_Therapeutic_Indications-1024x1024.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_IASO_Bio_Lupus_Nephritis_Therapeutic_Indications-150x150.png 150w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_IASO_Bio_Lupus_Nephritis_Therapeutic_Indications.png 1254w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>IASO Bio<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>Investigator-initiated data disclosure<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>Autologous BCMA CAR T<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>Equecabtagene autoleucel (eque-cel)<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>BCMA<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Refractory lupus nephritis<\/p>\n<h4>Summary<\/h4>\n<p>Recovered source-gap item: IASO Bio disclosed November 10 investigator-initiated data in three severe refractory lupus nephritis patients with nine months of follow-up. All achieved at least partial renal remission; two complete renal remission. These are uncontrolled early observations.<\/p>\n<p>The China-origin disclosure describes biopsy-confirmed refractory or relapsed disease, cyclophosphamide plus fludarabine lymphodepletion and one infusion of equecabtagene autoleucel. All three discontinued glucocorticoids and immunosuppressants by two months. CRS was grade 1; no ICANS, serious adverse event or death was reported in these three. The presented poster was November 9.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> plasma-cell depletion may support sustained immune reset in refractory renal autoimmunity. Support: concordant renal and systemic measures with treatment withdrawal. Against: n=3, no comparator, short follow-up and background effects of lymphodepletion.<\/p>\n<p><strong>Interpretation B:<\/strong> early remissions may not persist or generalize to diverse biopsy classes. Support: selection and investigator-study design. Against: all three had difficult prior disease and several concordant endpoints. Longer renal function and proteinuria trajectories, repeat biopsy, relapse, infection and hypogammaglobulinemia follow-up, and controlled trials would upgrade or falsify the efficacy thesis.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>Lupus nephritis is immune-mediated kidney injury. Eque-cel is an autologous BCMA CAR-T therapy intended to deplete pathogenic plasma-cell lineages; it is approved in China for relapsed myeloma, not lupus nephritis.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Three patients, nine months of follow-up, uncontrolled.<\/li>\n<li>All three reached at least partial renal remission and two reached complete renal remission.<\/li>\n<li>The poster was presented November 9; the disclosure followed on November 10.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>A small but concordant early signal for plasma-cell-directed cell therapy in refractory lupus nephritis. Replication in larger controlled cohorts is the next gate.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 4 of 5. Signal Direction: uncertain. Confidence in Facts: moderate. Confidence in Interpretation: low.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Recovered source-gap item: IASO Bio disclosed November 10 investigator-initiated data in three severe refractory lupus nephritis patients with nine months of follow-up. All achieved at least partial renal remission; two complete renal remission. These&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4235,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[1441,775,209],"class_list":["post-4215","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-equecabtagene-autoleucel","tag-iaso-bio","tag-lupus-nephritis"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4215","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4215"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4215\/revisions"}],"predecessor-version":[{"id":4248,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4215\/revisions\/4248"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4235"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4215"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4215"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4215"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}